- Home
- AEMD vs APVO Comparison
AEMD vs APVO Comparison
Compare AEMD & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEMD
- APVO
- Stock Information
- Founded
- AEMD 1984
- APVO 2016
- Country
- AEMD United States
- APVO United States
- Employees
- AEMD N/A
- APVO N/A
- Industry
- AEMD Medical/Dental Instruments
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- AEMD Health Care
- APVO Health Care
- Exchange
- AEMD Nasdaq
- APVO Nasdaq
- Market Cap
- AEMD 4.1M
- APVO 4.1M
- IPO Year
- AEMD N/A
- APVO N/A
- Fundamental
- Price
- AEMD $1.33
- APVO $3.06
- Analyst Decision
- AEMD Buy
- APVO Strong Buy
- Analyst Count
- AEMD 2
- APVO 1
- Target Price
- AEMD $28.75
- APVO $5,920.00
- AVG Volume (30 Days)
- AEMD 519.4K
- APVO 191.0K
- Earning Date
- AEMD 08-13-2025
- APVO 08-07-2025
- Dividend Yield
- AEMD N/A
- APVO N/A
- EPS Growth
- AEMD N/A
- APVO N/A
- EPS
- AEMD N/A
- APVO N/A
- Revenue
- AEMD N/A
- APVO N/A
- Revenue This Year
- AEMD N/A
- APVO N/A
- Revenue Next Year
- AEMD N/A
- APVO N/A
- P/E Ratio
- AEMD N/A
- APVO N/A
- Revenue Growth
- AEMD N/A
- APVO N/A
- 52 Week Low
- AEMD $1.10
- APVO $2.81
- 52 Week High
- AEMD $8.44
- APVO $381.10
- Technical
- Relative Strength Index (RSI)
- AEMD 42.14
- APVO 38.28
- Support Level
- AEMD $1.10
- APVO $3.01
- Resistance Level
- AEMD $1.40
- APVO $3.18
- Average True Range (ATR)
- AEMD 0.11
- APVO 0.16
- MACD
- AEMD 0.07
- APVO 0.19
- Stochastic Oscillator
- AEMD 47.92
- APVO 45.45
About AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.